Therapeutic options for infantile hemangioma are limited. The nonselective beta-adrenergic receptor antagonist propranolol is an effective therapy for infantile hemangiomas. However, systemic propranolol carries a risk of serious side effects, including bradycardia, hypoglycemia, arrhythmias, hypotension and bronchospasm. Recently, treatment of infantile hemangioma with topical timolol (nonselective beta-blocker similar to propranolol) has been reported. We treated successfully the perineal ulcerative hemangioma with topical timolol. We believe that timolol is a safe and effective topical agent and should be strongly considered as one of good therapeutic options for hemagnioma.